Brolucizumab, or equally as difficult to remember, RTH258, was shown to be superior to Eylea in recent clinical trials. The research from the phase 2 clinical trials was presented at the American Academy of Ophthalmology last week.
The highlights from these trials were that even at a 12 week dosing interval, more patients were found to have less active wet AMD disease than Eylea patients.
How is this anti-VEGF different than the others?
Three main differences.
Three main differences.
1. It’s molecular size.
2. The drug concentration.
3. The time between injections.
Brolucizumab is the smallest anti-VEGF molecule tested in humans. The small size allows for better tissue penetration and the ability to give higher drug concentrations. These two things lengthen the treatment effect, increasing the time between injections.
If all goes well, Novartis plans to submit RTH258 for FDA approval in 2018 potentially making it available to the market in 2019. (via)
